The Quantellect read.As of Nov 19, 2026, 5 active firms cover UroGen Pharma Ltd: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $33.00 to $75.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $55.20 sits 85% above the current $29.79. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.32 next quarter toward $2.56 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$55.20
+85.3% upside
Average target across 5 active firms as of Nov 19, 2026 vs $29.79 current
Highest Target$75.00
Average Target$55.20
Lowest Target$33.00
Detailed analyst forecasts for URGN
Showing 1–6 of 6 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate URGN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
URGN EPS & revenue forecast
EPS · NEXT QUARTER
$0.32
Range $0.01 – $0.68 · 5 analysts · -169% YoY
Next period, 5 analysts expect UroGen Pharma Ltd to earn $0.32 a share (range $0.01 – $0.68), versus $-0.47 a year earlier. Full-year consensus is $-0.30, growing to $2.56 the year after.
REVENUE · NEXT QUARTER
$114.5M
Range $103.5M – $128.7M · 5 analysts · +125% YoY
Revenue is expected to reach $114.5M (range $103.5M – $128.7M), +124.7% year-over-year. Full-year consensus is $319.6M, rising to $534.8M next year.
Top analysts covering UroGen Pharma Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on URGN.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$56.00+88.0% to target
Overall win rate
53%
+ Follow
#2
Paul Choi
Goldman Sachs · Rank #110
Neutral
$48.00+61.1% to target
Overall win rate
52%
+ Follow
#3
George Farmer
Scotiabank · Rank #311
Buy
$47.00+57.8% to target
Overall win rate
44%
+ Follow
#4
Leland Gershell
Oppenheimer · Rank #404
Buy
$50.00+67.8% to target
Overall win rate
35%
+ Follow
#5
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$75.00+151.8% to target
Overall win rate
36%
+ Follow
URGN stock forecast FAQ
What is URGN's average 12-month price target?+
The 5 active firms with a live target average $55.20 for UroGen Pharma Ltd over the next 12 months, ranging from a $75.00 high to a $33.00 low, as of Nov 19, 2026.
Is URGN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for URGN?+
The Street-high target is $75.00 (HC Wainwright & Co.), and the Street-low is $33.00 (D. Boral Capital). The average of all 5 active-firm targets is $55.20.
How many active Wall Street firms cover URGN?+
5 active firms have a recognized rating on UroGen Pharma Ltd as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering URGN?+
Among analysts who currently cover URGN, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $56.00 target.
What is UroGen Pharma Ltd's projected EPS for next quarter?+
The consensus estimate is $0.32 per share (range $0.01 – $0.68) across 5 analysts. Full-year EPS is projected at $-0.30, rising to $2.56 the following year.
How much revenue is UroGen Pharma Ltd expected to report next quarter?+
Consensus revenue is $114.5M (range $103.5M – $128.7M). Full-year revenue is projected at $319.6M, growing to $534.8M next year.
Have analysts been upgrading or downgrading URGN lately?+
As of Nov 19, 2026, 5 of 5 active firms rate URGN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their URGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.